US2008131454A1PendingUtilityA1

Methods and Compositions for the Treatment of Rhinovirus Infections with Carrageenan

42
Assignee: MARINOMED BIOTECHNOLOGIE GMBHPriority: Dec 5, 2006Filed: Dec 5, 2006Published: Jun 5, 2008
Est. expiryDec 5, 2026(~0.3 yrs left)· nominal 20-yr term from priority
Inventors:Andreas GrassauerEva Prieschl-GrassauerChristiane MeierAlexander Pretsch
A61P 31/16A61K 31/731A61P 11/06
42
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention provides the use of carrageenan or mixtures thereof for the manufacture of an antiviral pharmaceutical composition for the treatment of rhinovirus infections.

Claims

exact text as granted — not AI-modified
1 . A method for the treatment or prophylaxis of a rhinovirus infection comprising administering to a subject a pharmaceutical composition comprising carrageenan. 
     
     
         2 . The method of  claim 1 , wherein the administration is topical or mucosal. 
     
     
         3 . The method of  claim 2 , wherein the pharmaceutical composition is in the form of a nose spray, powder, drop, or gargle solution. 
     
     
         4 . The method of  claim 1 , wherein the preparation comprises a pharmaceutical carrier or additive. 
     
     
         5 . The method of  claim 1 , wherein the preparation is further defined as comprising 0.01% and 20% carrageenan. 
     
     
         6 . The method of  claim 5 , wherein the preparation is further defined as comprising 0.1% and 10% carrageenan. 
     
     
         7 . The method of  claim 6 , wherein the preparation is further defined as comprising 0.5% and 5% carrageenan. 
     
     
         8 . The method of  claim 1 , wherein the preparation comprises at least two different antiviral components. 
     
     
         9 . The method of  claim 8 , wherein one of the antiviral components is cellulose sulfate. 
     
     
         10 . The method of  claim 1 , wherein the preparation is sterile. 
     
     
         11 . The method of  claim 1 , wherein the total carrageenan concentration in the preparation is comprised of at least 80% lambda-, kappa-, and/or iota-carrageenan. 
     
     
         12 . The method of  claim 11 , wherein the total carrageenan concentration in the preparation is comprised of at least 90% lambda-, kappa-, and/or iota-carrageenan. 
     
     
         13 . The method of  claim 12 , wherein the total carrageenan concentration in the preparation is comprised of at least 95% lambda-, kappa-, and/or iota-carrageenan. 
     
     
         14 . The method of  claim 13 , wherein the total carrageenan concentration in the preparation is comprised of at least 99% lambda-, kappa-, and/or iota-carrageenan. 
     
     
         15 . The method of  claim 11 , wherein the total carrageenan concentration in the preparation is comprised of at least 80% iota-carrageenan. 
     
     
         16 . The method of  claim 15 , wherein the total carrageenan concentration in the preparation is comprised of at least 90% iota-carrageenan. 
     
     
         17 . The method of  claim 16 , wherein the total carrageenan concentration in the preparation is comprised of at least 95% iota-carrageenan. 
     
     
         18 . The method of  claim 17 , wherein the total carrageenan concentration in the preparation is comprised of at least 99% iota-carrageenan. 
     
     
         19 . The method of  claim 1 , wherein the preparation is further defined as comprising a lambda-carrageenan homopolymer. 
     
     
         20 . The method of  claim 1 , wherein the preparation is further defined as comprising a kappa-carrageenan homopolymer. 
     
     
         21 . The method of  claim 1 , wherein the preparation is further defined as comprising an iota-carrageenan homopolymer. 
     
     
         22 . The method of  claim 1 , further defined as a method for the treatment of a rhinovirus infection. 
     
     
         23 . The method of  claim 22 , wherein the rhinovirus infection is an acute or chronic rhinovirus infection. 
     
     
         24 . The method of  claim 1 , wherein the preparation is further defined as comprising an agent for the treatment or prophylaxis of asthma. 
     
     
         25 . The method of  claim 1 , wherein the subject is human. 
     
     
         26 . A hygiene or sanitation article comprising iota-, lambda- and/or kappa-carrageenan. 
     
     
         27 . The article of  claim 26 , further defined as comprising a homopolymer of iota-, lambda-, and/or kappa-carrageenan. 
     
     
         28 . The article of  claim 26 , further defined as a facial hygiene or sanitation article. 
     
     
         29 . The article of  claim 28 , further defined as a facial or sanitation article adapted for use in the oral and/or nasal area. 
     
     
         30 . The article of  claim 29 , further defined as an article adapted for topical or mucosal use. 
     
     
         31 . The article of  claim 30 , further defined as a nose spray, powder, drop, or gargle solution.

Join the waitlist — get patent alerts

Track US2008131454A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.